Product: Le Cru du Clocher raw milk cheddar cheese
Companies: Le Fromage au Village Inc.
Issue: Food ? Microbial contamination ? Listeria
Category: Dairy
What to do: Do not consume, use, sell, serve, or distribute recalled products
Audience: General public
Recall class: Class 1
Affected products
Brand
Product
Size
UPC
Codes
Le Fromage au
Village
Le Cru du Clocher raw
milk cheddar cheese
160 g
6 73536 00051 8
* All lots manufactured prior to:
« DATE DE FAB. 10 AL 2022 »
Le Fromage au
Village
Le Cru du Clocher raw
milk cheddar cheese
variable
none
* All lots manufactured prior to:
« DATE DE FAB. 10 AL 2022 »
Issue
The food recall warning issued on 2023-02-11 has been amended to correctly identify the affected products. The corrections for these products are marked by an asterisk (*).
The affected products are being recalled from the marketplace due to possible Listeria contamination.
The recalled products have been sold in Ontario, Quebec, online and may have been distributed in other provinces and territories.
What you should do
If you think you became sick from consuming a recalled product, contact your healthcare provider
Check to see if you have recalled products
Do not consume, serve, use, sell, or distribute recalled products
Recalled products should be thrown out or returned to the location where they were purchased
Food contaminated with Listeria monocytogenes may not look or smell spoiled but can still make you sick. Symptoms can include vomiting, nausea, persistent fever, muscle aches, severe headache and neck stiffness. Pregnant women, the elderly and people with weakened immune systems are particularly at risk. Although infected pregnant women may experience only mild, flu-like symptoms, the infection can lead to premature delivery, infection of the newborn or even stillbirth. In severe cases of illness, people may die.
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...
YOUR LEGAL RIGHTS MAY BE AFFECTED
There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...